Skip to main content

Regeneron Pharmaceuticals’ Dupixent Has Multi-Billion-Dollar Potential: Polen Capital

Investment manager Polen Capital is bullish on Regeneron Pharmaceuticals (REGN), which has six FDA-approved medicines and numerous product candidates in a range of diseases.
Data & News supplied by www.cloudquote.io
Stock quotes supplied by Barchart
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms and Conditions.